Olanzapin: Et nyt antipsykotikum

Ugeskrift for Laeger

Volumn 159, Issue 48, 1997, Pages 7160-7164

  Bredkjœr, Søren Rask ^a   Gerlach, Jes ^a  

^a Sct Hans Hospital   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; OLANZAPINE;

DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DYSKINESIA; DYSTONIA; EDEMA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PSYCHOSIS; SCHIZOPHRENIA; SHORT SURVEY; SIDE EFFECT;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; HUMANS; PIRENZEPINE; SCHIZOPHRENIA;

EID: 0030683672     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Gerlach J, Peacock L New antipsychotics: the present status. Int Clin Psychopharmacol 1995; 10: 39-48.
2. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC et al. Fadioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996; 14: 87-96.
3. Schotte A, Janssen PFM, Gommeren W, Luyten WHML, Van Compel P, Lesage AS et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 1996; 124: 57-73.
4. Roth BL, Craigo SC, Choudhary MS. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 1994; 268: 1403-10.
5. Fulton B, Goa KL. Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia. Drugs 1997; 53: 281-98
6. 1 values. J Pharmacol Exp Ther 1989; 251: 238-46.
7. Seeman P, Guan HC, Van Tol HHM. Dopamine D4 receptors elevated in schizophrenia. Nature 1993; 365: 441-5.
8. Moore NA, Tye NC, Axton MS. The behavioral pharmacology of olanzapine, a novel atypical antipsychotic agent. J Pharmacol Exp Ther 1992; 262: 545-51.
9. Deveney AM, Waddington JL. Comparison of the new atypical antipsychotics olanzapine and ICI 204,636 with clozapine on behavioural responses to the selective D1-like dopamine receptor agonist A 68930 and selective D2-like agonist RU 24213. Psychopharmacology 1996; 124: 40-9.
10. 2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology (i trykken).
11. Pilowsky LS, Busatto GF, Taylor M, Costa DC, Sharma T, Sigmundsson T et al. Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine - a 1231 IBZM single photon emission tomography study. Psychopharmacology 1996; 124: 148-53.
12. Stockton ME, Rasmussen K. Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmacology 1996; 14: 97-104.
13. Stockton ME, Rasmussen K Olanzapine, a novel atypical antipsychotic, reverses d-amphetamine-induced inhibition of midbrain dopamine cells. Psychopharmacology 1996; 124: 50-6.
14. Boyd D, Obermeyer BD, Nyhart Jr EH. Pharmakokinetics of olanzapine in healthy volunteers [abstract no. 120]. Pharmacologist 1993; 35: 176.
15. Bergstrom RF, Callaghan JT, Cerimele BJ. Pharmacokinetics of olanzapine in elderly and young [abstract]. Pharm Res 1995; 12(s): 358.
16. Patel BR, Nyhart JEH, Callaghan JT. Combined population pharmacokinetic analysis of olanzapine in healthy volunteers [abstract]. Pharm Res 1995; 12(s): 360.
17. Beasley CM, Tollefson GD, Tran PV, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1096; 14: 111-23.
18. Beasley CM, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: results of a double-blind, fixed dose olanzapine trial. Psychopharmacology 1996; 124: 159-67.
19. Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997; 154: 457-65.
20. Tran PV, Beasley TP, Tollefson GD, Crawford MD, Gusman S, Wood A. Acute and longterm results of the dose-ranging double-bind olanzapine trial [poster], (JM van Ree, SA Montgomery), eds. 20th Congress of the International College of Neuropsychopharmacology (CINP). Melbourne, Australien; Elsevier Science, 1996: 58.
21. Satterlee WG, Dellva MA, Beasley CM, Tran P, Tollefsong G. Effectiveness of olanzapine in long-term continuation treatment [poster], (JM van Ree, SA Montgomery), eds. 20th Congress of the International College of Neuropsychopharmacology (CINP) Melbourne, Australien: Elsevier Science, 1996: 59.
22. Baldwin DS, Montgomery SA. First clinical experience with olanzapine (LY 170053): results of an open-label safety and dose-ranging study in patients with schizophrenia. Int Clin Psychopharmacol 1995; 10: 239-44.
23. Ring BJ, Binkley SN, Vandenbranden M, Wrighton SA. In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A Br J Clin Pharmacol 1996; 41: 181-6.